350 related articles for article (PubMed ID: 25416282)
1. Retromer-dependent neurotransmitter receptor trafficking to synapses is altered by the Parkinson's disease VPS35 mutation p.D620N.
Munsie LN; Milnerwood AJ; Seibler P; Beccano-Kelly DA; Tatarnikov I; Khinda J; Volta M; Kadgien C; Cao LP; Tapia L; Klein C; Farrer MJ
Hum Mol Genet; 2015 Mar; 24(6):1691-703. PubMed ID: 25416282
[TBL] [Abstract][Full Text] [Related]
2. Endosomal traffic and glutamate synapse activity are increased in VPS35 D620N mutant knock-in mouse neurons, and resistant to LRRK2 kinase inhibition.
Kadgien CA; Kamesh A; Milnerwood AJ
Mol Brain; 2021 Sep; 14(1):143. PubMed ID: 34530877
[TBL] [Abstract][Full Text] [Related]
3. The Vps35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer.
Follett J; Norwood SJ; Hamilton NA; Mohan M; Kovtun O; Tay S; Zhe Y; Wood SA; Mellick GD; Silburn PA; Collins BM; Bugarcic A; Teasdale RD
Traffic; 2014 Feb; 15(2):230-44. PubMed ID: 24152121
[TBL] [Abstract][Full Text] [Related]
4. Role of the VPS35 D620N mutation in Parkinson's disease.
Mohan M; Mellick GD
Parkinsonism Relat Disord; 2017 Mar; 36():10-18. PubMed ID: 27964832
[TBL] [Abstract][Full Text] [Related]
5. Formation of retromer transport carriers is disrupted by the Parkinson disease-linked Vps35 D620N variant.
Cui Y; Yang Z; Flores-Rodriguez N; Follett J; Ariotti N; Wall AA; Parton RG; Teasdale RD
Traffic; 2021 Apr; 22(4):123-136. PubMed ID: 33347683
[TBL] [Abstract][Full Text] [Related]
6. Parkinson's disease-linked
Chen X; Kordich JK; Williams ET; Levine N; Cole-Strauss A; Marshall L; Labrie V; Ma J; Lipton JW; Moore DJ
Proc Natl Acad Sci U S A; 2019 Mar; 116(12):5765-5774. PubMed ID: 30842285
[TBL] [Abstract][Full Text] [Related]
7. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.
Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR
Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203
[TBL] [Abstract][Full Text] [Related]
8. VPS35 and retromer dysfunction in Parkinson's disease.
Rowlands J; Moore DJ
Philos Trans R Soc Lond B Biol Sci; 2024 Apr; 379(1899):20220384. PubMed ID: 38368930
[TBL] [Abstract][Full Text] [Related]
9. Retromer binding to FAM21 and the WASH complex is perturbed by the Parkinson disease-linked VPS35(D620N) mutation.
McGough IJ; Steinberg F; Jia D; Barbuti PA; McMillan KJ; Heesom KJ; Whone AL; Caldwell MA; Billadeau DD; Rosen MK; Cullen PJ
Curr Biol; 2014 Jul; 24(14):1670-1676. PubMed ID: 24980502
[TBL] [Abstract][Full Text] [Related]
10. VPS35 regulates cell surface recycling and signaling of dopamine receptor D1.
Wang C; Niu M; Zhou Z; Zheng X; Zhang L; Tian Y; Yu X; Bu G; Xu H; Ma Q; Zhang YW
Neurobiol Aging; 2016 Oct; 46():22-31. PubMed ID: 27460146
[TBL] [Abstract][Full Text] [Related]
11. Parkin mediates the ubiquitination of VPS35 and modulates retromer-dependent endosomal sorting.
Williams ET; Glauser L; Tsika E; Jiang H; Islam S; Moore DJ
Hum Mol Genet; 2018 Sep; 27(18):3189-3205. PubMed ID: 29893854
[TBL] [Abstract][Full Text] [Related]
12. The Retromer Supports AMPA Receptor Trafficking During LTP.
Temkin P; Morishita W; Goswami D; Arendt K; Chen L; Malenka R
Neuron; 2017 Apr; 94(1):74-82.e5. PubMed ID: 28384478
[TBL] [Abstract][Full Text] [Related]
13. Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration.
Tsika E; Glauser L; Moser R; Fiser A; Daniel G; Sheerin UM; Lees A; Troncoso JC; Lewis PA; Bandopadhyay R; Schneider BL; Moore DJ
Hum Mol Genet; 2014 Sep; 23(17):4621-38. PubMed ID: 24740878
[TBL] [Abstract][Full Text] [Related]
14. Altered striatal dopamine levels in Parkinson's disease VPS35 D620N mutant transgenic aged mice.
Vanan S; Zeng X; Chia SY; Varnäs K; Jiang M; Zhang K; Saw WT; Padmanabhan P; Yu WP; Zhou ZD; Halldin C; Gulyás B; Tan EK; Zeng L
Mol Brain; 2020 Dec; 13(1):164. PubMed ID: 33261640
[TBL] [Abstract][Full Text] [Related]
15. VPS35, the Retromer Complex and Parkinson's Disease.
Williams ET; Chen X; Moore DJ
J Parkinsons Dis; 2017; 7(2):219-233. PubMed ID: 28222538
[TBL] [Abstract][Full Text] [Related]
16. VPS35 and α-Synuclein fail to interact to modulate neurodegeneration in rodent models of Parkinson's disease.
Chen X; Tsika E; Levine N; Moore DJ
Mol Neurodegener; 2023 Aug; 18(1):51. PubMed ID: 37542299
[TBL] [Abstract][Full Text] [Related]
17. Endosomal dysfunction in iPSC-derived neural cells from Parkinson's disease patients with VPS35 D620N.
Bono K; Hara-Miyauchi C; Sumi S; Oka H; Iguchi Y; Okano HJ
Mol Brain; 2020 Oct; 13(1):137. PubMed ID: 33032646
[TBL] [Abstract][Full Text] [Related]
18. Impaired neurogenesis in the hippocampus of an adult VPS35 mutant mouse model of Parkinson's disease through interaction with APP.
Jiang M; Tu HT; Zhang K; Zhang W; Yu WP; Xu J; Tan EK; Guo KH; Zeng L
Neurobiol Dis; 2021 Jun; 153():105313. PubMed ID: 33636388
[TBL] [Abstract][Full Text] [Related]
19. (D620N) VPS35 causes the impairment of Wnt/β-catenin signaling cascade and mitochondrial dysfunction in a PARK17 knockin mouse model.
Chiu CC; Weng YH; Huang YZ; Chen RS; Liu YC; Yeh TH; Lu CS; Lin YW; Chen YJ; Hsu CC; Chiu CH; Wang YT; Chen WS; Liu SY; Wang HL
Cell Death Dis; 2020 Nov; 11(11):1018. PubMed ID: 33257649
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial and Clearance Impairment in p.D620N VPS35 Patient-Derived Neurons.
Hanss Z; Larsen SB; Antony P; Mencke P; Massart F; Jarazo J; Schwamborn JC; Barbuti PA; Mellick GD; Krüger R
Mov Disord; 2021 Mar; 36(3):704-715. PubMed ID: 33142012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
